SCHEMBL346504

SCHEMBL346504

CC(C)(C)OC(=O)N1CCC(CN)C1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.49
HPGD P15428 1/20 0.48
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
RECQL P46063 1/20 0.46
EPHX1 P07099 1/20 0.46
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GPR119 Q8TDV5 3/20 0.43
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
FAAH O00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6197 1.00 NR1H2 (0.49) NR1H2HPGDKDM4EPKMMEN1
SCHEMBL321665 1.00 NR1H2 (0.49) NR1H2HPGDKDM4EPKMMEN1
Hydrochloric Acid SCHEMBL28558235 0.98 NR1H2 (0.48) NR1H2HPGDKDM4EPKMMEN1
Hydrochloric Acid SCHEMBL1290905 0.98 NR1H2 (0.48) NR1H2HPGDKDM4EPKMMEN1
SCHEMBL28110777 0.92 HPGD (0.51) NR1H2HPGDKDM4EPKMMEN1
SCHEMBL640559 0.91 MEN1 (0.54) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL1192567 0.91 MEN1 (0.54) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL481736 0.91 MEN1 (0.54) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL103083 0.90 HPGD (0.54) NR1H2HPGDKDM4EPKMMAPT
Hydrochloric Acid SCHEMBL31587983 0.89 MEN1 (0.53) NR1H2HPGDMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 801 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036730-A Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof 中山大学 2026-05-15 CN claimed
CN-113912594-B Nitrothiophene methylamine optical isomer and medical application thereof 中国人民解放军军事科学院军事医学研究院 2023-08-04 CN claimed
CN-122036730-A Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof 中山大学 2026-05-15 CN disclosed
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 EP disclosed
US-12565476-B2 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors Revolution Medicines, Inc. (US) 2026-03-03 US disclosed
EP-4700021-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT Sapiensbio Inc. (KR) 2026-02-25 EP disclosed
EP-4161931-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-02-18 EP disclosed
US-20260035354-A1 PIPERIDINEDIONE DERIVATIVES INNOCURE THERAPEUTICS, INC. (KR) 2026-02-05 US disclosed
EP-4682148-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2026-01-21 EP disclosed
EP-3638678-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2025-12-03 EP disclosed
US-12479838-B2 D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-11-25 US disclosed
EP-1213281-B1 NOVEL AMIDE DERIVATIVES BANYU PHARMA CO LTD (JP) 2004-02-18 EP disclosed
WO-2003045942-A2 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-06-05 WO disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
EP-1213281-A1 NOVEL AMIDE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-06-12 EP disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed
EP-1131288-A1 PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-09-12 EP disclosed
US-6166015-A Pyrrolidine derivatives-CCR-3 receptor antagonists SYNTEX (U.S.A.) INC. (US) 2000-12-26 US disclosed
WO-2000031032-A1 PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2000-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035354-A1 PIPERIDINEDIONE DERIVATIVES CRBN, PSMC1, PSME3 NR1H2 2144/4885HPGD 3125/4885KDM4E 303/4885
US-12479838-B2 D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof DRD3, ADRB3, VDR NR1H2 403/4885HPGD 1173/4885KDM4E 4472/4885
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A NR1H2 3566/4885HPGD 2513/4885KDM4E 2528/4885
US-12565476-B2 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors PTPN5, PTPN6, PTPN2 NR1H2 162/4885HPGD 4501/4885KDM4E 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.